PVLA

Palvella Therapeutics Stock Analysis

AI Rating

Good
  • Quality6/10
  • Growth↓ 2/10
  • Value↑ 6/10
Palvella Therapeutics sales and earnings growth
PVLA Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 40.68%
  • FCF Y/Y↓ -76.31%
Palvella Therapeutics gross and profit margin trends
PVLA Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 9.12%
Palvella Therapeutics net debt vs free cash flow
PVLA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -5.7

Palvella Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks